Fujirebio Diagnostics, Incorporated
$2.2M 10 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Orchard Therapeutics North America
Orchard Therapeutics North America reported $2,243,214.01 across General Payments, Research, and Ownership to 69 physicians and teaching hospitals across 77 transactions.
- $2.2M Top quartile payer
- All-tracks total
- 77 Below-median volume
- Transactions
- 69 Below-median reach
- Recipients
- #425
- of 1,925 companies
Orchard Therapeutics North America reported $2,243,214.01 across all CMS Open Payments tracks (General + Research + Ownership) to 69 physicians and teaching hospitals in Program Year 2024 - ranking #425 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $14,046.59, averaging $32.5K per recipient.
How Orchard Therapeutics North America's $2.2M all-tracks total breaks down
Orchard Therapeutics North America's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
22/100
Total payments
F
31/100
Transaction volume
F
11/100
Physician reach
F
10/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer orchard-therapeutics-north-america Orchard Therapeutics North America
$2.2M · #425/1,925 · 0.0% industry · PY2024
- TOT $2.2M
- RANK #425
- SHARE 0.0%
- TXN 77
- RCP 69
- CAT 3
- GEN $14.0K
- TOP1 28.6%
- PY 2024
Volume peers
Nearest volume peer: Fujirebio Diagnostics, Incorporated ($2.2M)
Orchard Therapeutics North America sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Orchard Therapeutics North America
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Orchard Therapeutics North America, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
The 3-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Travel and Lodging" at $8.4K, accounting for 60.1% of this company's General Payments and 24 transactions.
General Payment Breakdown by Type
"Travel and Lodging" leads Orchard Therapeutics North America's 3-category general-payment breakdown at $8.4K, 60.1% of the reported total.
How Orchard Therapeutics North America divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Travel and Lodging | $8.4K | 24 | 60.1% |
| Consulting Fee | $3.0K | 1 | 21.6% |
| Food and Beverage | $2.6K | 44 | 18.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $12,325.83 (87.7%) of $14,046.59 in this company's General Payments records across 17 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Orchard Therapeutics North America
The five named recipients with the highest reported General Payments from this company
- 1
Laura Adang
$4,018.76 across 18 reported transactions
- 2
Louis Cohen
$3,040.00 across 1 reported transactions
- 3
Jennifer Braun
$2,359.10 across 14 reported transactions
- 4
Lisa Tennyson Emrick
$1,746.40 across 8 reported transactions
- 5
Suhag Parikh
$1,161.57 across 8 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Orchard Therapeutics North America ranks #425 of 1,925 by total payments (top 22% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #778 of 1,838 by HHI (top 42% most concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Reichert, Inc. : $186.8K total payments, HHI 1880
- Canary Medical USA LLC : $754.5K total payments, HHI 1873
- Avyxa Pharma, LLC : $17.2K total payments, HHI 1863
- Amarin Pharma Inc. : $199.3K total payments, HHI 1855
- HydroCision, Inc. : $117.1K total payments, HHI 1854
- C. R. Bard, Inc. & Subsidiaries : $865.6K total payments, HHI 1853
- Orchard Therapeutics North America (this company) : $14.0K total payments, HHI 1853
- Zest Holdings, LLC : $571.1K total payments, HHI 1849
- Turing Medical Technologies : $128.3K total payments, HHI 1844
- Hartmann USA, Inc. : $45.9K total payments, HHI 1833
- Arrow International, Inc. : $376.6K total payments, HHI 1833
- Current Health Inc. : $10.2K total payments, HHI 1822
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Orchard Therapeutics North America's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Orchard Therapeutics North America.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Orchard Therapeutics North America.
Showing 6 of 1,924 companies with CMS-reported payment data.
New World Medical,inc.
$2.2M 3,180 recipients
Compare payment profiles
Ceribell, Inc.
$2.3M 1,173 recipients
Compare payment profiles
Smarter Devices, LLC
$2.2M 0 recipients
Compare payment profiles
United Imaging Healthcare North America, Inc.
$2.2M 66 recipients
Compare payment profiles
Aimmune Therapeutics, Inc.
$2.3M 32,592 recipients
Compare payment profiles
Put this to use
Orchard Therapeutics North America ranks #425 of 1,925 by all-tracks total payments, led by "Travel and Lodging".
- See where Orchard Therapeutics North America sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Travel and Lodging" spend across every manufacturer, not just Orchard Therapeutics North America. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.